Volume 4.06 | Feb 19

Hematopoiesis News 4.06 February 19, 2013
Hematopoiesis News

     In this issue: Publications | ReviewsScience News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
TOP STORY
(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Investigators showed that a canonical IDH1 mutant, IDH1 R132H, promotes cytokine independence and blocks differentiation in hematopoietic cells. These effects can be recapitulated by the (R)-enantiomer of 2-hydroxyglutarate [(R)-2-HG], but not (S)-2-HG, despite the fact that (S)-2-HG more potently inhibits enzymes previously linked to the pathogenesis of IDH mutant tumors, such as the 5′-methylcytosine hydroxylase TET2. [Science] Abstract | Press Release

StemSpan ACF: The WORLD'S FIRST Plasma Component-Free Hematopoietic Expansion Medium. Come learn more.
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Proliferation-Dependent Alterations of the DNA Methylation Landscape Underlie Hematopoietic Stem Cell Aging
To explore the relationship between age-associated hematopoietic stem cell (HSC) decline and the epigenome, investigators examined global DNA methylation of HSCs during ontogeny in combination with functional analysis. [Cell Stem Cell] Abstract | Graphical Abstract

PKR Regulates Proliferation, Differentiation and Survival of Murine Hematopoietic Stem/Progenitor Cells
To determine the role of PKR in hematopoiesis, scientists developed transgenic mouse models that express either human PKR, or a dominant-negative PKR mutant specifically in hematopoietic tissues. [Blood] Abstract

Perivascular Support of Human Hematopoietic Cells
Mesenchymal stem/stromal cells (MSCs), which support hematopoiesis in culture, are themselves derived in part from perivascular cells. In order to define their direct role in hematopoiesis, researchers tested the ability of purified human CD146+ perivascular cells, as compared to unfractionated MSCs and CD146- cells, to sustain human hematopoietic stem and progenitor cells in co-culture. [Blood] Abstract

Cotransplantation with Specific Populations of Spina Bifida Bone Marrow Stem/Progenitor Cells Enhances Urinary Bladder Regeneration
The authors demonstrated the role of two specific populations of bone marrow stem/progenitor cells used in combination with a synthetic elastomeric scaffold that provides a unique and alternative means to current bladder regeneration approaches. [Proc Natl Acad Sci USA] Abstract | Press Release

Regulation of Hematopoietic Stem Cell Behavior by the Nanostructured Presentation of Extracellular Matrix Components
Investigators showed that human hematopoietic stem and progenitor cell adhesion depends on the type of ligand, i.e., the type of extracellular matrix molecule, and the lateral, nanometer-scaled distance between the ligands (while the ligand type influenced the dependency on the latter). [PLoS One] Full Article

SNS-032 Inhibits Mammalian Target of Rapamycin Complex 1 (mTORC1)/mTORC2 Activity in Acute Myeloid Leukemia Cells and Has Synergistic Activity with Perifosine against Akt
Researchers aimed to characterize the in vitro effects of SNS-032, used alone and in combination with an Akt inhibitor perifosine, against acute myeloid leukemia cells and identified the mechanism involved. [J Hematol Oncol] Abstract | Full Article

Busulfan Conditioning Enhances Engraftment of Hematopoietic Donor-Derived Cells in the Brain Compared with Irradiation
Scientists compared hematopoietic donor cell brain engraftment after bone marrow transplants in busulfan- or irradiation-conditioned mice. Significantly more donor-derived microglial cells engrafted posttransplant in busulfan-conditioned brain compared with the irradiated, in both the short and long term. [Bone Marrow Transplant] Abstract

CLINICAL RESEARCH

Evolving Risk of Therapy-Related Acute Myeloid Leukemia following Cancer Chemotherapy among Adults in the United States, 1975-2008
Among 426,068 adults initially treated with chemotherapy for first primary malignancy, the authors identified 801 therapy-related acute myeloid leukemia cases, 4.70-times more than expected in the general population. [Blood] Abstract | Press Release

Long Term Outcome and Evaluation of Organ Function in Pediatric Patients Undergoing Haploidentical and Matched Related Hematopoietic Cell Transplantation for Sickle Cell Disease
Investigators report the long-term hematological response and organ function in patients undergoing a matched related donor and haploidentical donor hematopoietic stem cell transplant (HSCT) for severe sickle cell disease. Their data demonstrated long-term hematologic improvements after HSCT for the patients with sustained engraftment. [Biol Blood Marrow Transplant] Abstract

Allogeneic Hematopoietic Cell Transplantation for Neuroblastoma: The CIBMTR Experience
The Center for International Blood and Marrow Transplant Research (CIBMTR) conducted a retrospective review of 143 allogenic-hematopoietic cell transplantations (allo-HCT) for neuroblastoma. Patients were categorized into two different groups: those who had not (Group 1) and had (Group 2) undergone a prior autologous-HCT. One-year and five-year OS were 59% and 29% for Group 1 and 50% and 7% for Group 2, respectively. [Bone Marrow Transplant] Abstract

Free Wallchart: Identification Of Colonies Derived From Mouse Hematopoietic Progenitors

REVIEWS
Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation
The authors review recent advances in the understanding of the molecular and biologic aspects of primary plasma cell leukemia and summarized therapeutic progress occurring over the past two decades. [Biol Blood Marrow Transplant] Abstract
SCIENCE NEWS

Positive Data from Celldex’s Phase I Study of CDX-301 Support Initiation of Pilot Study in Hematopoietic Stem Cell Transplantation
Celldex Therapeutics, Inc. presented final results from a Phase I study of CDX-301 (recombinant human Flt3L) in healthy volunteers that strongly support the initiation of a pilot study in hematopoietic stem cell transplantation. [Press release from Celldex Therapeutics, Inc. discussing research presented at the American Society for Blood and Marrow Transplantation 2013 BMT Tandem Meetings, Salt Lake City] Press Release

Gamida Cell’s NiCord® Demonstrates Successful Engraftment in Patients with Hematological Malignancies in Phase I/II Study
Gamida Cell announced the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company’s proprietary NAM technology. [Press release from Gamida Cell discussing research presented at the American Society for Blood and Marrow Transplantation 2013 BMT Tandem Meetings, Salt Lake City] Press Release

INDUSTRY NEWS

Lentigen Receives U.S. Orphan Drug Designation for Novel Gene Therapy for Glioblastoma Multiforme
Lentigen Corporation announced that that the U.S. Food and Drug Administration has granted orphan drug status to P140K methylguanine methyltransferase transduced human CD34 cells for bone marrow protection in the treatment of glioblastoma multiforme. [PR Newswire Association LLC] Press Release

Xenon Announces Appointment of EVP, Research & Development
Xenon Pharmaceuticals Inc. announced the appointment of Gary J. Bridger PhD as Executive Vice President (EVP), Research and Development. As a co-founder and CSO of AnorMED, he was responsible for the development of MOZOBIL, a hematopoietic stem cell mobilizing agent for non-Hodgkin’s lymphoma and multiple myeloma patients, from discovery through completion of phase III trials. [Xenon Pharmaceuticals Inc.] Press Release

Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge
Osiris Therapeutics, Inc. announced the successful conclusion of a patent challenge in Australia by an opponent whose identity under Australian law was not disclosed. The patent at issue covers the administration of mesenchymal stem cells, including Prochymal® (remestemcel-L), for the treatment of inflammatory conditions involving the gastrointestinal tract, including Crohn’s disease and ulcerative colitis. [Osiris Therapeutics, Inc.] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW International Society for Stem Cell Research (ISSCR) 11th Annual Meeting
June 12-15, 2013
Boston, United States

Visit our events page to see a complete list of events in the hematopoietic community.

JOB OPPORTUNITIES

Postdoctoral Position – Gene Regulation in the Hematopoietic and Immune Systems (Lund University)

Postdoctoral Positions – Stem Cell Biology (Children’s Hospital Oakland Research Institute)

Postdoctoral Position – Hematopoietic and Malignant Stem Cells (Istanbul University)

Postdoctoral Position – Stem Cell Biology (Washington University of Medicine)

Postdoctoral Research Associate – Stem Cell Biology and Epigenetics (University of Wisconsin)

Postdoctoral Position – Myeloproliferative Neoplasms (Mount Sinai Medical Center)

Postdoctoral Position – Stem Cell Research (University of Washington)

PhD Studentship (University Medical Center Groningen)


PhD Studentship – Hematopoietic Development and Bioinformatics (Karolinska Institute, Department of Laboratory Medicine)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us

Suite 201 – 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada